New cIAP Antibodies Pave The Way In Human Cancer Research

Tue, 03/09/2010 - 09:38

Apoptosis inhibitors are a well studied group of proteins that have been implicated in the formation of several types of human tumor. The most commonly studied IAP (inhibitor of apoptosis protein) is the Survivin antibody. However, our apoptosis antibody catalog at Novus Biologicals is constantly being updated to reflect the growing list of newer proteins. cIAP1 and cIAP2 antibodies are among the more recent of our anti-apoptosis products.

All IAP proteins are characterized by their ability to suppress cell death via their BIR (baculoviral IAP repeat), a novel domain consisting of around 70 amino acids. Some have an additional CARD and/or RING domains. They prevent apoptosis by inhibition of TNF and other pro-apoptosis proteins. This is done by the binding and inactivation of various caspases (cell death proteases).

The cIAP protein mediates TRAF2 ubiquitination following the receptor binding of TNF-alpha. It has two isoforms, structurally similar to XIAP. Each has three BIR motifs which bind to caspase-3 and caspase-7. cIAP 1/2 form a heteromeric complex which is then recruited to the death receptor TNF-R2 (tumor necrosis factor receptor 2) via the TNF receptor associated factors 1 and 2 (TRAF1 and TRAF2).

cIAP is inhibited by HtrA2 (also called Omi) which acts by catalytic cleaving of the protein. Smac/DIABLO is another negative regulator which works by enhancing the autoubiquitination action of cIAP.

Immunohistochemistry: cIAP2 Antibody Immunohistochemistry: cIAP2 Antibody

The cIAP1 and 2 immunoglobulins are recent additions to our antibody database at Novus Biologicals, and have been used in studies into human cancers. In January 2010, cIAP2 antibodies were used in a study showing retinoic acid having a possible protective role in the battle against breast cancer.

Novus Biologicals offers many cIAP2 reagents for your research needs including:


Blog Topics